{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:47:41Z","timestamp":1791863261008,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.neo.2026.101359","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:15:31Z","timestamp":1789388131000},"page":"101359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-1699","authenticated-orcid":false,"given":"Manon A.","family":"Simard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elba","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garc\u00eda-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Yekelchyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schmelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Berges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balca R.","family":"Mardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ockfen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-9550","authenticated-orcid":false,"given":"Felix","family":"Geist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Reusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Jordana-Ariza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Esparr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2996-7475","authenticated-orcid":false,"given":"Tolulope","family":"Apata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-6567","authenticated-orcid":false,"given":"Cristina","family":"Teixido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Rico-Past\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hijazo-Pechero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5274-4659","authenticated-orcid":false,"given":"Marina","family":"Querol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Morfouace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8866-9881","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"Molina-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-499X","authenticated-orcid":false,"given":"Noem\u00ed","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2378-0498","authenticated-orcid":false,"given":"Niki","family":"Karachaliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neo.2026.101359_bib0001","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1200\/JCO.2015.64.2777","article-title":"Impaired c-met receptor degradation mediated by MET exon 14 mutations in non-small-cell lung cancer","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.neo.2026.101359_bib0002","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.neo.2026.101359_bib0003","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting MET dysregulation in cancer","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.neo.2026.101359_bib0004","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","article-title":"MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer mutation Consortium","volume":"14","author":"Guo","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.neo.2026.101359_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","article-title":"Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: results from the European Thoracic Oncology Platform (ETOP) Lungscape project","volume":"111","author":"Bubendorf","year":"2017","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.neo.2026.101359_bib0006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41392-023-01403-w","article-title":"SYK-mediated epithelial cell state is associated with response to c-met inhibitors in c-met-overexpressing lung cancer","volume":"8","author":"Zhou","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.neo.2026.101359_bib0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12967-023-03999-7","article-title":"Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer","volume":"21","author":"Sun","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neo.2026.101359_bib0008","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.10.003","article-title":"Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?","volume":"61","author":"Wu","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.neo.2026.101359_bib0009","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.neo.2026.101359_bib0010","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.neo.2026.101359_bib0011","article-title":"Characterization of non-small-cell lung cancers with MET exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns","volume":"5","author":"Lee","year":"2021","journal-title":"JCo Precis. Oncol."},{"key":"10.1016\/j.neo.2026.101359_bib0012","article-title":"Landscape and clonal dominance of Co-occurring genomic alterations in non-small-cell lung cancer harboring MET exon 14 skipping","volume":"5","author":"Le","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.neo.2026.101359_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2021.12.016","article-title":"Targeting un-MET needs in advanced non-small cell lung cancer","volume":"164","author":"Coleman","year":"2022","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.neo.2026.101359_bib0014","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.neo.2026.101359_bib0015","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.neo.2026.101359_bib0016","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.neo.2026.101359_bib0017","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/S2213-2600(21)00084-9","article-title":"Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study","volume":"9","author":"Lu","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.neo.2026.101359_bib0018","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","article-title":"Acquired METD1228V mutation and resistance to MET inhibition in lung cancer","volume":"6","author":"Bahcall","year":"2016","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.neo.2026.101359_bib0019","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.jtho.2019.06.023","article-title":"Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors In vitro","volume":"14","author":"Fujino","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.neo.2026.101359_bib0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11523-022-00931-9","article-title":"Phase I study evaluating Glesatinib (MGCD265), an inhibitor of MET and AXL, in patients with non-small cell lung cancer and other advanced solid tumors","volume":"18","author":"Kollmannsberger","year":"2023","journal-title":"Target. Oncol."},{"issue":"24","key":"10.1016\/j.neo.2026.101359_bib0021","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","article-title":"Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus Erlotinib versus Erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer","volume":"33","author":"Scagliotti","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101359_bib0022","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejca.2022.11.010","article-title":"Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors","volume":"179","author":"Riedel","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"11, Supplement","key":"10.1016\/j.neo.2026.101359_bib0023","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jtho.2023.09.107","article-title":"OA21.06 ctDNA dynamics, prognostic markers and resistance mechanisms in Tepotinib-treated METex14 skipping NSCLC in the VISION trial","volume":"18","author":"Le","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.neo.2026.101359_bib0024","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1158\/1078-0432.CCR-20-2861","article-title":"MET exon 14-altered lung cancers and MET inhibitor resistance","volume":"27","author":"Guo","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.neo.2026.101359_bib0025","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101359_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-15-0189","article-title":"Tumor-derived cell lines as molecular models of cancer pharmacogenomics","volume":"14","author":"Goodspeed","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101359_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jmp4010007","article-title":"Fluorescence In situ hybridization (FISH) for the characterization and monitoring of primary cultures from Human tumors","volume":"4","author":"Rom\u00e1n-Llad\u00f3","year":"2023","journal-title":"J. Mol. Pathol."},{"key":"10.1016\/j.neo.2026.101359_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100192","article-title":"Clinical utility of body fluids for multiplexed detection of genetic alterations in cancer patients","volume":"5","author":"Beatriz Garc\u00eda","year":"2024","journal-title":"J. Liquid Biopsy"},{"issue":"6_Supplement","key":"10.1016\/j.neo.2026.101359_bib0029","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1158\/1538-7445.AM2024-6497","article-title":"Abstract 6497: molecular characterization and drug sensitivity of a gastric FGFR2-TACC2 and a pancreatic KRAS p.G12C primary culture","volume":"84","author":"Garcia-Roman","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101359_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.101063","article-title":"Spatial profiling of METex14-altered NSCLC under tepotinib treatment: shifting the immunosuppressive landscape","volume":"57","author":"Simard","year":"2024","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.neo.2026.101359_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101832","article-title":"SHP2 Inhibition influences therapeutic response to Tepotinib in tumors with MET alterations","volume":"23","author":"Pudelko","year":"2020","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.neo.2026.101359_bib0032","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/1878-0261.12861","article-title":"Multiplex RNA-based detection of clinically relevant MET alterations in advanced non-small cell lung cancer","volume":"15","author":"Aguado","year":"2021","journal-title":"Mol. Oncol."},{"issue":"22","key":"10.1016\/j.neo.2026.101359_bib0033","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-11-1157","article-title":"A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3","volume":"17","author":"Liu","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.neo.2026.101359_bib0034","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-09-3620","article-title":"Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency","volume":"70","author":"McDermott","year":"2010","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.neo.2026.101359_bib0035","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-10-1623","article-title":"Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors","volume":"71","author":"Qi","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.neo.2026.101359_bib0036","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1016\/j.csbj.2023.11.028","article-title":"Structural insight into the macrocyclic inhibitor TPX-0022 of c-met and c-src","volume":"21","author":"Qu","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"8","key":"10.1016\/j.neo.2026.101359_bib0037","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00432-024-05920-1","article-title":"Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma","volume":"150","author":"Li","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101359_bib0038","article-title":"The role of tumor-associated macrophages in lung cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Front. Immunol."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:25:34Z","timestamp":1791861934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S1476558626000916"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101359","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101359"}}